Dr. Bob Dagher has more than 20 years of leadership across clinical development, medical affairs, and regulatory strategy in neuropsychiatry, neuroimmunology, and rare disease. He has served as chief medical officer at four biotech companies, leading programs from first-in-human through Phase 3 and BLA submission across mood disorders, psychotic disorders, neurodegeneration, ALS, MS, and rare CNS diseases. Trained in psychiatry at Boston University Medical Center, he holds his M.D. from Bordeaux University and St. Joseph University School of Medicine.
As Chief Medical Officer at Clinilabs, Dr. Dagher brings a distinguished record of leading scientifically complex CNS drug development programs from first-in-human studies through Phase 3 and regulatory submission, precisely the full-development continuum that defines Clinilabs’ mission as the industry’s leading neurotherapeutic CRO, helping sponsor partners accelerate their CNS programs with the precision, integrity, and CNS depth that only Clinilabs delivers.
